Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of 8-Hydroxyquinoline Derivatives Active Against Somatic V658F Mutant JAK1-Dependent Cells.

Archiv der Pharmazie - 1 Dec 2016

Kiss Róbert, Bajusz Dávid, Baskin Rebekah, Tóth Katalin, Monostory Katalin, Sayeski Peter P, Keserű György M

Abstract excerpt

Janus kinases (JAKs) and their gain-of-function mutants have been implicated in a range of oncological, inflammatory, and autoimmune conditions, which has sparked great research interest in the discovery and development of small-molecule JAK inhibitors. Two molecules are currently marketed as JAK inhibitors, but due to the displayed side effects (owing to their suboptimal selectivities among the various JAK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Death
Share to Cells, Cultured

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 1

Share to Molecular Docking Simulation

Share to Protein Kinase Inhibitors

Share to Structure-Activity Relationship

Source

Identifiers

PMID: 27862215
DOI: 10.1002/ardp.201600246

Genes

JAK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of 8-Hydroxyquinoline Derivatives Active Against Somatic V658F Mutant JAK1-Dependent Cells.PMID 27862215Read ↗

The chemical class of quinazoline compounds provides a core structure for the design of anticytomegaloviral kinase inhibitorsSemantic proximity Read ↗

New alkanesulfonate-based quinazolinone-acetohydrazide scaffolds: Rational design, synthesis, molecular docking, anticancer properties and potential EGFR and its T790M/L858R mutants inhibitors.Semantic proximity Read ↗

Integrated Ligand and Structure based approaches towards developing novel Janus Kinase 2 inhibitors for the treatment of myeloproliferative neoplasmsSemantic proximity Read ↗

Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).Semantic proximity Read ↗

Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 InhibitorsSemantic proximity Read ↗

The use of structural biology in Janus kinase targeted drug discovery.Semantic proximity Read ↗

Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019).Semantic proximity Read ↗

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617FSemantic proximity Read ↗

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFRWT, EGFRT790M, and EGFRL858R).Semantic proximity Read ↗

Macrocyclization of Broad-Spectrum Kinase Inhibitor Bosutinib leads to Potent and Selective Quinoline-based HIPK4 Inhibitor AZ137Semantic proximity Read ↗

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.Semantic proximity Read ↗

Tetrahydroisoquinolines – an updated patent review for cancer treatment (2016 – present)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.